Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mcneil healthcare (ireland) limited, tallaght, high street, office 5, 6 & 7, block 5, dublin, irska - loperamidklorid - raspadljiva tableta za usta - 2 mg - urbroj: jedna raspadljiva tableta za usta sadrži 2 mg loperamidklorida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mcneil healthcare (ireland) limited, tallaght, high street, office 5, 6 & 7, block 5, dublin, irska - loperamidklorid simetikon - tableta - 2 mg + 125 mg - urbroj: jedna tableta sadrži 2 mg loperamidklorida i 125 mg dimetikona kao simetikon

Europska Unija - hrvatski - EMA (European Medicines Agency)

gilead sciences ireland unlimited company - lenacapavir sodium - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 i 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 i 5.

Hrvatska - hrvatski - Ecolab

ecolab deutschland gmbh -

Europska Unija - hrvatski - EMA (European Medicines Agency)

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - svi ostali terapeutski proizvodi - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Europska Unija - hrvatski - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastična sredstva - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europska Unija - hrvatski - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europska Unija - hrvatski - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - uklanjanje neuromuskularne blokade izazvane rokoronom ili vekuronomom. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europska Unija - hrvatski - EMA (European Medicines Agency)

piramal critical care b.v. - sugammadex sodium - neuromuskularna blokada - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.